NAN – Morgans rates the stock as Add
The target price falls to $4.86 from $5.43, the Add rating is retained after a significant share price fall.
Read More
Nanosonics Limited
Nanosonics Limited is an innovator in infection prevention. The company’s unique, automated trophon® EPR high-level disinfection device has paved the way around the world in setting a new standard of care in ultrasound probe disinfection practices. trophon is a global solution for reducing cross-contamination between patients and reducing the spread of Healthcare Acquired Infections (HAIs).
With a growing trend around the world towards stricter ultrasound probe reprocessing guidelines, traditional systems have been falling behind in their ability to meet today’s demanding requirements. Nanosonics cutting edge technology used in trophon has really disrupted the disinfection market and was the first major innovation in ultrasound probe HLD in more than 20 years.
Spotlight Videos
Where Are The Opportunities In Australian Small-Caps?
All Nanosonics Limited Content
News
Where Are The Opportunities In Australian Small-Caps?
Sam Twidale, Portfolio Manager for the DNR Capital Australian Emerging Companies Fund, explains why he believes recent volatility in equity markets has provided some excellent opportunities in the smaller cap sector.
Read More
Three Businesses To Weather The Storm
Andrew Page of Strawman.com highlights three Australian companies with net cash and zero debt that should offer safe harbour at this time.
Read More
Nanosonics Post Reporting Season Update
DNR Capital Portfolio Manager Sam Twidale last discussed Nanosonics (ASX:NAN) back in April 2019. Since that time the share price has rallied strongly from the mid $4 level back in April to touching $7 since reporting in late August.The DNR Capital Australian Emerging Companies Fund currently holds a 6% position in Nanosonics.
Read More
trophon How The Technology Works
trophon’s high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H2O2) mist that kills bacteria, fungi and viruses.
Read More
Analyst Views
NAN – Morgans rates the stock as Add
The broker maintains its Add rating and $5.43 target price.
Read More
NAN – Morgans rates the stock as Add
The broker lowers forecasts, mainly in FY21, to reflect an exchange rate adjustment to consumables. The target price have been revised down to $6.57 from $6.69.
Read More
NAN – Morgans rates the stock as Upgrade to Add from Hold
Even though the August profit release may cause some price weakness, Morgans prefers to get in early with a upgrade to Add, given the share price is -10% below the broker's target price of $6.92. The post-result weakness may arise from limited hospital access in the last few months.
Read More
NAN – Morgans rates the stock as Downgrade to Hold from Add
Share price of Nanosonics has been relatively stable during this period of pandemic-generated volatility, observes Morgans.
Read More
NAN – Morgans rates the stock as Downgrade to Hold from Add
The share price has rallied over 30% in the last month and Morgans downgrades to Hold from Add. Second half operating earnings (EBITDA) are forecast to be less than the first half so, potentially, some weakness is likely to follow when the company reports in late August.
Read More
